Presentation at 18th Annual World Cancer Congress

AI SummaryClose X

Coiled Therapeutics plc announced that its Executive Chairman will present on AO-252, a novel TACC3 inhibitor, at the 18th Annual World Cancer Congress on April 16, 2026. The presentation will highlight AO-252's potent activity in multiple solid tumors, including brain metastases, and its potential to address significant unmet needs in oncology. This follows recent clinical trial updates demonstrating superior efficacy and durable responses for AO-252 in heavily pre-treated patients, with the company planning to initiate dose expansion cohorts in lead indications during 2026.

Disclaimer*

UK 100

Latest directors dealings